Literature DB >> 16195807

Progress and challenges in childhood brain tumors.

Roger J Packer1.   

Abstract

Although many challenges lie ahead, there has been definite progress made in the management of childhood brain tumors. Some of these advances have increased progression-free and overall survival. Other advances, while not improving survival, have resulted in a better quality of life for long-term survivors. Probably the best example of progress is manifest in the outcome of children with medulloblastoma. Seventy percent, and in some subsets as high as 80% of children with this disease can be expected to be cured, compared to approximately 50% three decades ago. This improvement in disease control has been associated with a reduction in the dose of radiotherapy for many patients and possibly an improved quality of survival. For other tumor types, especially brain stem gliomas, there has been little progress made. A primary challenge in the years ahead will be how to integrate biologic discoveries into the care of children for brain tumors, with the hope that molecular biologically based therapy will be more effective and improve the quality of life for survivors.

Entities:  

Mesh:

Year:  2005        PMID: 16195807     DOI: 10.1007/s11060-005-6745-9

Source DB:  PubMed          Journal:  J Neurooncol        ISSN: 0167-594X            Impact factor:   4.130


  16 in total

1.  Adjuvant chemotherapy for medulloblastoma: the first multi-centre control trial of the International Society of Paediatric Oncology (SIOP I).

Authors:  D M Tait; H Thornton-Jones; H J Bloom; J Lemerle; P Morris-Jones
Journal:  Eur J Cancer       Date:  1990-04       Impact factor: 9.162

2.  Postoperative chemotherapy without irradiation for ependymoma in children under 5 years of age: a multicenter trial of the French Society of Pediatric Oncology.

Authors:  J Grill; M C Le Deley; D Gambarelli; M A Raquin; D Couanet; A Pierre-Kahn; J L Habrand; F Doz; D Frappaz; J C Gentet; C Edan; P Chastagner; C Kalifa
Journal:  J Clin Oncol       Date:  2001-03-01       Impact factor: 44.544

3.  Hyperfractionated radiotherapy for children with brainstem gliomas: a pilot study using 7,200 cGy.

Authors:  R J Packer; J C Allen; J L Goldwein; J Newall; R A Zimmerman; J Priest; T Tomita; D E Mandelbaum; B H Cohen; J L Finlay
Journal:  Ann Neurol       Date:  1990-02       Impact factor: 10.422

4.  The treatment of medulloblastoma. Results of a prospective randomized trial of radiation therapy with and without CCNU, vincristine, and prednisone.

Authors:  A E Evans; R D Jenkin; R Sposto; J A Ortega; C B Wilson; W Wara; I J Ertel; S Kramer; C H Chang; S L Leikin
Journal:  J Neurosurg       Date:  1990-04       Impact factor: 5.115

5.  Metastasis stage, adjuvant treatment, and residual tumor are prognostic factors for medulloblastoma in children: conclusions from the Children's Cancer Group 921 randomized phase III study.

Authors:  P M Zeltzer; J M Boyett; J L Finlay; A L Albright; L B Rorke; J M Milstein; J C Allen; K R Stevens; P Stanley; H Li; J H Wisoff; J R Geyer; P McGuire-Cullen; J A Stehbens; S B Shurin; R J Packer
Journal:  J Clin Oncol       Date:  1999-03       Impact factor: 44.544

6.  Carboplatin and vincristine chemotherapy for children with newly diagnosed progressive low-grade gliomas.

Authors:  R J Packer; J Ater; J Allen; P Phillips; R Geyer; H S Nicholson; R Jakacki; E Kurczynski; M Needle; J Finlay; G Reaman; J M Boyett
Journal:  J Neurosurg       Date:  1997-05       Impact factor: 5.115

7.  Preliminary results from a phase II trial of conformal radiation therapy and evaluation of radiation-related CNS effects for pediatric patients with localized ependymoma.

Authors:  Thomas E Merchant; Raymond K Mulhern; Matthew J Krasin; Larry E Kun; Tani Williams; Chenghong Li; Xiaoping Xiong; Raja B Khan; Robert H Lustig; Frederick A Boop; Robert A Sanford
Journal:  J Clin Oncol       Date:  2004-08-01       Impact factor: 44.544

Review 8.  Mutism and pseudobulbar symptoms after resection of posterior fossa tumors in children: incidence and pathophysiology.

Authors:  I F Pollack; P Polinko; A L Albright; R Towbin; C Fitz
Journal:  Neurosurgery       Date:  1995-11       Impact factor: 4.654

9.  Central nervous system atypical teratoid/rhabdoid tumors of infancy and childhood: definition of an entity.

Authors:  L B Rorke; R J Packer; J A Biegel
Journal:  J Neurosurg       Date:  1996-07       Impact factor: 5.115

10.  Randomized phase III trial in childhood high-grade astrocytoma comparing vincristine, lomustine, and prednisone with the eight-drugs-in-1-day regimen. Childrens Cancer Group.

Authors:  J L Finlay; J M Boyett; A J Yates; J H Wisoff; J M Milstein; J R Geyer; S J Bertolone; P McGuire; J M Cherlow; M Tefft
Journal:  J Clin Oncol       Date:  1995-01       Impact factor: 44.544

View more
  12 in total

Review 1.  Treatment developments and the unfolding of the quality of life discussion in childhood medulloblastoma: a review.

Authors:  Thora Gudrunardottir; Birgitta Lannering; Marc Remke; Michael D Taylor; Elizabeth M Wells; Robert F Keating; Roger J Packer
Journal:  Childs Nerv Syst       Date:  2014-02-26       Impact factor: 1.475

2.  Family factors associated with academic achievement deficits in pediatric brain tumor survivors.

Authors:  Emily Ach; Cynthia A Gerhardt; Maru Barrera; Mary Jo Kupst; Eugene A Meyer; Andrea F Patenaude; Kathryn Vannatta
Journal:  Psychooncology       Date:  2012-10-12       Impact factor: 3.894

3.  Lack of prognostic significance of survivin in pediatric medulloblastoma.

Authors:  Roberta Soares Faccion; Regina Moreira Ferreira; Marília Fornaciari Grabois; Theresinha Carvalho Fonseca; Jose Antonio de Oliveira; Raquel Ciuvalschi Maia
Journal:  Pathol Oncol Res       Date:  2011-06-17       Impact factor: 3.201

4.  Calmodulin-kinases regulate basal and estrogen stimulated medulloblastoma migration via Rac1.

Authors:  Monika A Davare; Takeo Saneyoshi; Thomas R Soderling
Journal:  J Neurooncol       Date:  2010-11-24       Impact factor: 4.130

5.  Medulloblastoma: clinicopathologic evaluation of 42 pediatric cases.

Authors:  Yeşim Ertan; Murat Sezak; Bengü Demirağ; Mehmet Kantar; Nazan Cetingül; Tuncer Turhan; Yusuf Erşahin; Saffet Mutluer; Yavuz Anacak; Taner Akalin
Journal:  Childs Nerv Syst       Date:  2009-01-13       Impact factor: 1.475

Review 6.  Herpes simplex virus oncolytic therapy for pediatric malignancies.

Authors:  Gregory K Friedman; Joseph G Pressey; Alyssa T Reddy; James M Markert; G Yancey Gillespie
Journal:  Mol Ther       Date:  2009-04-14       Impact factor: 11.454

7.  Inhibition of cyclin-dependent kinase 6 suppresses cell proliferation and enhances radiation sensitivity in medulloblastoma cells.

Authors:  Susan L Whiteway; Peter S Harris; Sujatha Venkataraman; Irina Alimova; Diane K Birks; Andrew M Donson; Nicholas K Foreman; Rajeev Vibhakar
Journal:  J Neurooncol       Date:  2012-11-09       Impact factor: 4.130

8.  Polo-like kinase 1 (PLK1) inhibition suppresses cell growth and enhances radiation sensitivity in medulloblastoma cells.

Authors:  Peter S Harris; Sujatha Venkataraman; Irina Alimova; Diane K Birks; Andrew M Donson; Jeffrey Knipstein; Adrian Dubuc; Michael D Taylor; Michael H Handler; Nicholas K Foreman; Rajeev Vibhakar
Journal:  BMC Cancer       Date:  2012-03-05       Impact factor: 4.430

9.  Institutional experience of paediatric high-grade central nervous system tumours: an analysis of 74 patients and review of the literature.

Authors:  Faruk Guclu Pinarli; Aynur Oguz; Ceyda Karadeniz; Arzu Okur; Avni Sarac; Kemali Baykaner; Huseyin Bora; Aylar Poyraz
Journal:  Contemp Oncol (Pozn)       Date:  2012-02-29

10.  Integrated genomic analysis identifies the mitotic checkpoint kinase WEE1 as a novel therapeutic target in medulloblastoma.

Authors:  Peter S Harris; Sujatha Venkataraman; Irina Alimova; Diane K Birks; Ilango Balakrishnan; Brian Cristiano; Andrew M Donson; Adrian M Dubuc; Michael D Taylor; Nicholas K Foreman; Philip Reigan; Rajeev Vibhakar
Journal:  Mol Cancer       Date:  2014-03-24       Impact factor: 27.401

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.